A traditional Chinese medicine preparation for treating connective tissue disease-associated interstitial lung disease

Abstract

The invention belongs to the technical field of traditional Chinese medicine, and specifically relates to a traditional Chinese medicine preparation for treating connective tissue disease-related interstitial lung disease. The traditional Chinese medicine composition includes the following ingredients and their weight parts: 20-40 parts of Astragalus membranaceus, 5-20 parts of Anemarrhenae, 5-20 parts of Bupleurum, 5-20 parts of Cimicifuga, 5-15 parts of Platycodon grandiflorum, and 1-10 parts of Schisandra chinensis. 10-25 parts of salvia miltiorrhiza, 10-20 parts of angelica root, and 3-9 parts of licorice. Also includes Hive 10‑20 servings. The traditional Chinese medicine composition of the present invention can effectively treat connective tissue disease-related interstitial lung disease, and can effectively reduce pulmonary fibrosis.

Description

technical field [0001] The invention belongs to the technical field of traditional Chinese medicine, and in particular relates to a traditional Chinese medicine preparation for treating interstitial lung disease associated with connective tissue disease. Background technique [0002] Interstitial lung disease (ILD) is a group of diffuse lung diseases that mainly involve the pulmonary interstitium, alveoli and / or bronchioles. ILD is a worldwide problem. Looking at the international guidelines for the past ten years, the confidence in the treatment of ILD is seriously insufficient. It is a difficult disease that seriously endangers human health in today's society. ILD is not an independent disease, it includes more than 200 diseases. The main clinical manifestations are progressive exertional shortness of breath, restrictive ventilatory dysfunction with reduced diffusion function, hypoxemia, and diffuse lesions in both lungs on imaging, and eventually develop into diffuse pul...

AI Technical Summary

Problems solved by technology

In view of the fact that the pathological type of connective tissue disease-associated interstitial lung disease is mainly common interstitial pneumonia, which is consistent with the pathological type of idiopathic pulmonary fibrosis, clinically try to use pirfenidone to treat connective tissue disease. disease-related interstitial lung disease, but the feedback on the treatment effect is not good, and its side effects are obvious, especially photosensitivity, liver function and gastrointestinal damage

At present, the diagnosis and treatment of connective tissue disease-associated interstitial lung disease with integrated traditional Chinese and Western medicine is still the consensus of the domestic medical community, and the clinical results are very good

Images